Ravicti Clinical Trial

Clinical Trial Announcement

The open label study of glycerol phenylbutyrate (“Ravicti”) has been expanded to include children with Creatine Transporter Deficiency (SLC6A8 mutations) that experience seizures. To learn more about the study, visit https://www.clinicaltrials.gov/study/NCT04937062. ACD will host an informational webinar on May 10, 2024 at 2:00 pm ET in which the trial investigator will share a presentation, questions from the audience will be answered, and details on how to express an interest in participating will be shared. From the trial summary, “This study is to evaluate the use of glycerol phenylbutyrate for monogenetic developmental epileptic encephalopathies (DEEs). DEEs are characterized by epilepsy and developmental delay in early life.”

IMPORTANT: This trial is “enrolling by invitation” from the trial investigator. To express your interest, please attend the webinar. 

Visit the Clinical Drug Trials section of creatineinfo.org/research-opportunities/ for updates on clinical trial opportunities.

Have questions? Visit creatineinfo.org/drug-development to learn more about drug development and the clinical trial process.

You may sign up for the May 10 webinar below: